News
Stay up to date on the latest crypto trends with our expert, in-depth coverage.
no_data1Amazon is Considering a $9 Billion Deal to Acquire Satellite Communications Company Globalstar. Here's Why Amazon, Apple, and Tesla Investors Should Pay Attention.2Exxon’s Guyana-Permian Engine Fuels 21% Earnings Growth—Is the 24 P/E Already Discounting a Squeeze?3Bitcoin’s Movement Compared to Oil’s Rally: Evaluating a Risk-Off Scenario
Flash
07:17
More than 600,000 prescriptions have been issued for oral semaglutide weight loss drug; Novo Nordisk CEO says weight loss drug market has only scratched the surfaceGolden Ten Data April 6｜According to the latest disclosed data from Novo Nordisk, prescriptions for its oral weight loss drug semaglutide currently exceed 600,000. UBS estimates that the combined revenue of Eli Lilly’s oral weight loss drug and Novo Nordisk’s oral version of semaglutide will reach approximately 5 billion USD in 2026. However, in the view of Novo Nordisk’s CEO, the weight loss drug market is vast, and the pharmaceutical industry has only scratched the surface. He stated that, including Novo Nordisk, Eli Lilly, and several U.S. producers of compound weight loss drugs, the current supply of weight loss medications can meet only 10% to 15% of the demand among obesity patients.
07:14
Data: BTC profit and loss trading ratio reaches 2.95, signaling a short-term price topChainCatcher news: According to Santiment data, the BTC profit-loss transaction ratio has reached 2.95, the highest level in 12 weeks, signaling a potential short-term price top.
07:02
Nansen adds cross-chain swap featureBlockBeats news, on April 6, on-chain data platform Nansen added a cross-chain swap feature. Users can now exchange Base tokens for Solana tokens.
News